Abstract Sox9 belongs to the family of Sry-related highmobility group box transcription factors controlling cell fate, cell proliferation and differentiation in various tissues, including cartilage, testis, the central nervous system, kidney, and gastrointestine. Mice conditionally lacking Sox9 have revealed essential roles for Sox9 in these tissues. To gain further insight into the role of Sox9 in different tissues and at different stages of development, we have generated a transgenic mouse line to express Sox9 in a Cre recombinase-dependent manner. The construct contained the human cytomegalovirus enhancer and chicken b-actin promoter, and a floxed monomeric red fluorescence protein 1 (mRFP1) cassette to direct ubiquitous expression of mRFP1. Cre expression removed the mRFP1 gene, allowing expression of Sox9 and enhanced green fluorescent protein. Expectedly, overexpression of Sox9 in chondrocytes using Col2a1-Cre mice suppressed chondrocyte hypertrophy, and delayed terminal differentiation and subsequent ossification. Misexpression of Sox9 in hypertrophic chondrocytes using Col10a1-Cre knock-in mice also delayed terminal differentiation. This Sox9 conditional transgenic mouse line will be a valuable tool to uncover tissue-specific and developmental stage-specific functions of Sox9.
Introduction
Sox9 is a transcription factor with a highly conserved Sryrelated high-mobility group DNA-binding domain and a transactivation domain. During mouse embryogenesis, Sox9 is expressed in a variety of tissues with a specific and temporal pattern, and controls cell lineage commitment and the subsequent cell proliferation and differentiation in these tissues. Recent mouse genetic approaches reveal that Sox9 plays essential roles in organogenesis in several organs. For example, Sox9 is required for testogenesis [1] , chondrogenesis [2] , and endocardial cushion formation in cardiogenesis [3] .
In chondrogenesis, Sox9 is expressed in all chondroprogenitors and chondrocytes, although its expression is diminished in hypertrophic chondrocytes. Our previous studies reveal that Sox9 regulates cell proliferation and differentiation at various steps of chondrogenesis [2, 4] . Inactivation of Sox9 in limb buds before chondrogenic mesenchymal condensation results in the complete absence of mesenchymal condensation and of subsequent cartilage and bone formation [2] . Moreover, inactivation of Sox9 in and after mesenchymal condensation arrests differentiation of condensed mesenchymal cells at condensations and impairs the proper proliferation and maturation of differentiated chondrocytes. Heterozygous Sox9 mutants are small and display delayed chondrogenic mesenchymal condensation and enlargement of the hypertrophic zone, in association with premature mineralization [5] . These data provide strong evidence that an adequate level of Sox9 is required for both mesenchymal condensation and the physiological inhibition of hypertrophic conversion of proliferating chondrocytes. Furthermore, transgenic mice expressing Sox9 ectopically in limb bud mesenchyme under the control of the Prx1 promoter exhibit ectopic cartilage formation in association with the induction of ectopic expression of Sox5 and Sox6, without any patterning defects in limb bud development [6] . The overexpression of Sox9 under the control of the Col2a1 promoter results in chondrodysplasia because of dramatic inhibition of chondrocyte proliferation [7] . These mouse genetic studies indicate that Sox9 is a master regulator of chondrogenesis and of the tightly controlled phases of proliferation and differentiation.
To study the in vivo functions of Sox9 using a tool that allows its controlled spatiotemporal expression, we developed conditional Sox9 transgenic mice, CAG-mRFP1 floxedSox9-EGFP (CAG-Sox9), to express Sox9 in a Cre recombinase-dependent manner. Using these mice, we generated mutant mice in which Sox9 was conditionally overexpressed or misexpressed in chondrocytes using Col2a1-Cre or Col10a1-Cre mice, resulting in impairment of endochondral bone formation.
Materials and methods

Generation of mutant mice
The CAG-mRFP1 floxed -Sox9-EGFP construct was generated by insertion of the following four DNA fragments into pcDNA3.1(-) (Invitrogen, CA): (1) a SalI-XhoI fragment containing the human CAG promoter derived from TriEX-2 (Novagen); (2) a NotI-SalI fragment encompassing an expression cassette that contained the loxP site-flanked mRFP1 gene and four tandem polyadenylation sites (4xpA) [8] ; (3) a SalI-NotI fragment containing the 3xHA-epitopetagged human Sox9 cDNA sequence; and (4) a BamHIAfIII fragment containing an internal ribosome entry site (IRES)-EGFP-pA sequence. The 12.7-kb PmeI-PmeI CAGmRFP1 floxed -Sox9-EGFP fragment was microinjected into the pronuclei of fertilized C57BL/6 oocytes to generate transgenic mice. Routine genotyping was performed by PCR using the primers 5 0 -TCCCCGACTACTTGAAGC TG-3 0 and 5 0 -CTTGGCCATGTAGGTGGTCT-3 0 , which amplify 317 bp of mRFP1.
A Col10a1 clone was isolated from a mouse C57BL/6 genomic DNA library. The targeting vector spanned a 13.1-kb fragment of the Col10a1 gene, and an IRES-Cre-pA/ FRT-flanked PGK-neo bpA cassette was inserted into a SmaI site within the 3 0 -untranslated region (UTR) in exon 3. An MC1-tk-pA herpes simplex virus thymidine kinase expression cassette was added onto the 3 0 arm of homology to enrich for homologous recombinants by negative selection with 1-(2 0 -deozy-2-fluoro 0 -b-D-arabinofuranosyl)-5-iodouracil (FIAU). The targeting vector was introduced into 129SvEv/C57BL/6 hybrid mouse ES cells [9] , and G418/ FIAU-resistant ES cell clones were initially screened by Southern blot analysis of EcoRV-digested genomic DNA by using 5 0 probe external to the region of vector homology. Mouse chimeras were generated by injection of mutant ES cell clones into C57BL/6 host blastocysts, and the chimeras obtained were bred with C57BL/6 mice to generate Col10a1-Cre knock-in heterozygous mice. Routine genotyping was performed by PCR using the primers 5 0 -TCCAA TTTACTGACCGTACACCA-3 0 and 5 0 -CCTGATCCTGG CAATTTCGGCTA-3 0 , which amplify 540 bp of Cre.
Histological analysis
For histological analysis, embryos were fixed in 4% paraformaldehyde and embedded in paraffin. Sections of 5 lm were stained with hematoxylin and eosin, Safranin O staining or the von Kossa reaction, and nuclear fast red.
Immunohistochemical staining was performed using a peroxidase-conjugated polymer (Zymed) and DAB with rabbit polyclonal anti-HA (1:500, Covance). RNA in situ hybridization analysis was performed as described previously [10] .
Quantitative RT-PCR Total RNA was extracted from the ribs of newborn mice using the TriPure isolation reagent (Roche Applied Science). 
Statistical analyses
We used the Student's t test to calculate P values. Differences were considered significant at P \ 0.05.
Results
Generation of CAG-Sox9 transgenic mice
To gain further insight into the tissue-specific and/or developmental stage-specific roles of Sox9 in vivo, we generated transgenic mice that overexpressed Sox9 (tagged with a hemagglutinin epitope, HA) conditionally under the control of the CAG promoter in a Cre recombinasedependent manner (Fig. 1a ). Sox9 expression under the control of the CAG promoter was blocked by an mRFP1 cassette that included four tandem polyadenylation sites (4xpA) to terminate transcription flanked by two loxP sites (flox). The expression of Cre recombinase in transgenic tissues led to the excision of the floxed mRFP1 cassette, resulting in the expression of Sox9 and EGFP. An IRES sequence was placed between Sox9 and the EGFP gene for access of ribosomes to the bicistronic RNA for parallel translation of both Sox9 and EGFP, rendering the EGFP protein a marker for the expression of HA-tagged Sox9 protein. Hence, this system allowed cell-specific overexpression or misexpression of Sox9 that was restricted to Cre Fig. 1 Generation of CAG-Sox9 transgenic mice. a The structure of the CAG-Sox9 transgene was shown. Two genes coding for fluorescent proteins, mRFP1 and EGFP, were separated by four tandem polyadenylation sites. Gene expression was controlled by the ubiquitous CAG promoter. The mRFP1 cassette was flanked by two loxP sites. Before Cre-mediated recombination, only mRFP1 was expressed. After Cre-mediated recombination, the mRFP1 cassette was excised and the 3xHA-tagged Sox9 and EGFP genes were expressed, instead of mRFP1. b Cre-mediated recombination was detected by color conversion from mRFP1 to EGFP in the cross of CAG-Sox9 mice with Sox9-Cre mice. Widespread EGFP expression was detected in endogenous Sox9-expressing tissues, such as skin (neonate), cartilage in forelimbs (E 18.5), intestine, pancreas, brain, and kidney (4-week-old old animals). c Genomic PCR analysis of mRFP1 and Cre recombinase transgenes. d Western blot analysis was performed using an anti-HA antibody. Exogenous 3xHA-tagged Sox9 was detected in the forelimbs of E16.5 CAG-Sox9; Sox9-Cre embryos. e Quantitative RT-PCR analysis of Sox9, Col2a1, and Aggrecan in the rib cartilages of newborn CAG-Sox9 and CAGSox9;Sox9-Cre mice (values shown as the average and standard deviation from five costal cartilages each; *P \ 0.05) recombinase-expressing cells and their cellular progeny. We then isolated eight CAG-Sox9 transgenic founders that expressed mRFP1 and were normal in phenotype. We selected one transgenic line that exhibited significant mRFP1 expression levels (data not shown). All tissues exhibited mRFP1 expression, indicating ubiquitous expression of the transgenic cassette. In general, hemizygous CAG-Sox9 mice were viable and fertile, and manifested no gross behavioral or phenotypic abnormalities.
We [2] , skin [11] , pancreas, kidney, digestive tract [12] , and brain [13] . In these tissues, fluorescent color conversion to EGFP from mRFP1 was observed in CAG-Sox9;Sox9-Cre mice (Fig. 1b) . CAGSox9;Sox9-Cre mice showed strong EGFP fluorescence, whereas tissues of their CAG-Sox9 littermates lacking the Sox9-Cre allele exhibited minimal EGFP fluorescence that can be considered as background levels. The presence of the mRFP1 and Cre transgenes in CAG-Sox9;Sox9-Cre mice was confirmed by PCR amplification from DNA extracted from mouse tails (Fig. 1c) . Western blot analysis showed that HA-tagged Sox9 protein was expressed in E16.5 forelimbs in CAG-Sox9;Sox9-Cre embryos, whereas this protein was not detectable in CAG-Sox9 littermates, demonstrating that HA-tagged Sox9 protein expression was efficiently induced by Cre recombinase (Fig. 1d) . Quantitative RT-PCR using RNA extracted from neonatal rib cartilages exhibited a significant increase in the levels of Sox9 and its downstream chondrocyte markers, such as Col2a1 and Aggrecan (Fig. 1e) . These data led us to conclude that the CAG-Sox9 conditional transgenic system worked in a Cre recombinase-dependent manner.
Conditional Sox9 overexpression in chondrocytes using Col2a1-Cre mice To verify the functions of Sox9 transgene in CAG-Sox9 mice, we crossed CAG-Sox9 mice with Col2a1-Cre transgenic mice, which express Cre recombinase in differentiated chondrocytes, to study the effect of Sox9 overexpression in Histological analysis of the metacarpal bones stained with hematoxylin and eosin. d Expression of chondrocyte markers in CAGSox9;Col2a1-Cre embryos. Histological analysis of the forelimbs of CAG-Sox9;Col2a1-Cre embryos stained with Safranin O, von Kossa at E17.5. Sections of forelimbs of E17.5 CAG-Sox9 and CAGSox9;Col2a1-Cre embryos were hybridized with Col2a1, Col10a1, and Mmp13 probes chondrocytes. We found that EGFP expression was detectable throughout the cartilaginous skeletal elements of CAG-Sox9;Col2a1-Cre embryos at E15.5 (Fig. 2a) . In CAG-Sox9;Col2a1-Cre embryos, HA-tagged Sox9 was detected in proliferating chondrocytes (Fig. 2b) . In addition, misexpression of Sox9 was also detected in hypertrophic chondrocytes, which revealed persistent expression of Sox9 throughout the growth plate (Fig. 2b) . Histological analysis showed that E15.5 CAG-Sox9;Col2a1-Cre embryos exhibited delayed hypertrophic conversion of the proliferating chondrocytes (Fig. 2c) and that E17.5 CAG-Sox9;Col2a1-Cre embryos exhibited an expansion of hypertrophic zone and a delay in the formation of the primary ossification center in forelimb skeletal elements (Fig. 2d) . The von Kossa staining showed that bone formation around the primary ossification center was delayed, and mineralized hypertrophic chondrocytes remained undegraded in the shaft in CAG-Sox9;Col2a1-Cre embryos. To characterize the phenotype further, we examined the expression of markers of specific stages of chondrocyte differentiation in the CAG-Sox9;Col2a1-Cre mice (Fig. 2d) . In situ hybridization revealed that the expression domain of Col10a1, which is a definitive molecular marker of hypertrophic chondrocytes, was expanded in CAG-Sox9;Col2a1-Cre embryos, although the expression domain of Col2a1 had no significant difference. The signal intensity of Mmp13, which is a marker of terminally differentiated hypertrophic chondrocytes, was significantly decreased in CAG-Sox9;Col2a1-Cre embryos compared with CAG-Sox9 embryos. These results indicate that terminal differentiation of hypertrophic chondrocytes and endochondral bone formation were inhibited with increased Sox9 expression in CAG-Sox9;Col2a1-Cre embryos.
Misexpression of Sox9 in hypertrophic chondrocytes resulted in delayed terminal differentiation
In CAG-Sox9;Col2a1-Cre embryos, overexpression of Sox9 in all differentiated chondrocytes resulted in delayed terminal differentiation of hypertrophic chondrocytes. In endochondral bone formation, expression of Sox9 is shut down in hypertrophic chondrocytes. To understand the biological significance of this shutdown of Sox9 expression in hypertrophic chondrocytes, we first generated Col10a1-Cre knock-in (Col10a1-Cre) mice, in which the Cre recombinase gene was inserted into the 3 0 UTR of the endogenous Col10a1 gene (Fig. 3a, b) . We first crossed Col10a1-Cre with the Rosa26 reporter (R26R) strain [14] , and in E16.5 Col10a1-Cre;R26R embryos, X-gal staining was specifically detected in hypertrophic zones (Fig. 3c) . Histological analysis revealed that all hypertrophic chondrocytes were stained with X-gal during chondrogenesis (Fig. 3d) . Col10a1-Cre mice displayed Cre expression and activity that were restricted to hypertrophic chondrocytes, resulting in specific expression of Sox9 in hypertrophic chondrocytes in CAG-Sox9;Col10a1-Cre embryos. Indeed, expression of the HA-tagged Sox9 protein was detected in hypertrophic chondrocytes using an anti-HA antibody in E16.5 CAG-Sox9;Col10a1-Cre embryos (Fig. 3e) . In E17.5 CAG-Sox9;Col10a1-Cre embryos, histological analysis revealed that endochondral bone formation was impaired in CAG-Sox9;Col10a1-Cre embryos, compared with CAG-Sox9 littermates (Fig. 3f) . The von Kossa staining indicated that mineralization eventually occurred in CAG-Sox9;Col10a1-Cre embryos, although the mineralized domain was markedly decreased. These observations suggest that terminal differentiation of hypertrophic chondrocytes was delayed as a consequence of Sox9 misexpression in hypertrophic chondrocytes.
To test this hypothesis, we analyzed the expression of genes that are markers of specific stages of chondrogenic differentiation in CAG-Sox9;Col10a1-Cre embryos. In situ hybridization revealed that the expression domains of Col10a1 and Mmp13 were expanded, and especially Mmp13 expression was extended to the bone marrow cavity in CAG-Sox9;Col10a1-Cre embryos (Fig. 3f) . These results indicate that misexpression of Sox9 in hypertrophic chondrocytes inhibited the terminal differentiation of hypertrophic chondrocytes and delay of cartilage replacement by bone.
Discussion
In this study, we generated a novel conditional transgenic mouse line expressing a Sox9 transgene in mouse organogenesis. Expression was driven by the ubiquitously expressed CAG promoter in a Cre recombinase-dependent manner. The use of a CAG promoter to drive the expression of the Sox9 transgene offers a significant advantage over an alternative design using a more restrictive promoter, as the activation of the Sox9 transgene will be determined by the expression pattern of the Cre transgene. Thus, CAG-Sox9 mice have the potential to be used in a broader range of studies by crossing with tissue-specific Cre mouse lines. Especially our conditional Sox9 expression system driven by the CAG promoter is well suited for persistent or ectopic expression of the Sox9 transgene throughout tissue development. In this study, we showed the expression of the Sox9 transgene in chondrocytes using Col2a1-Cre and in hypertrophic chondrocytes using Col10a1-Cre mice. In endochondral bone formation, we used Col2a1-Cre mice to demonstrate that the Sox9 transgene was active in all chondrocytes, including hypertrophic chondrocytes. Moreover, this system also has the significant advantage that EGFP fluorescence can be switched from mRFP1, thus allowing convenient monitoring of Sox9 transgene expression in CAG-Sox9 mice.
To confirm that overexpression of Sox9 transgene in CAG-Sox9 mice crossed with Cre driver mice functions in vivo, histological analyses were performed. A previous study showed that heterozygous Sox9 mouse mutants exhibit an expansion of the zone of hypertrophic chondrocytes in association with premature mineralization, which suggests that Sox9 inhibits the transition of proliferating chondrocytes to hypertrophy [5] . Our results indicate that persistent expression of Sox9 throughout the growth plate impairs hypertrophic conversion in CAG-Sox9;Col2a1-Cre embryos. This is consistent with the finding that Col2a1-Sox9 knockin mice display a phenotype of dwarfism with a marked delay in the transition of proliferating chondrocytes to hypertrophy [7] . Thus, we provided strong evidence that the shutdown of Sox9 expression just before hypertrophic conversion is required for the proper timing of the hypertrophic conversion of proliferating chondrocytes.
Terminal differentiation of hypertrophic chondrocytes is impaired by the overexpression of Sox9 in CAGSox9;Col2a1-Cre and CAG-Sox9;Col10a1-Cre mice. The phenotype of CAG-Sox9;Col10a1-Cre embryos resembled that of Sox9-overexpression mice using a Col10a1 BAC 5-kb fragments, respectively. c Whole-mount X-gal staining of E16.5 Col10a1-Cre;R26R embryos. Positive X-gal staining was detected in all hypertrophic zones in skeletons. d Histological analysis of forelimbs of Col10a1-Cre;R26R embryos stained with X-gal at E14.5. Positive X-gal staining was detected in all hypertrophic chondrocytes. e The expression of Sox9 driven by the transgene in hypertrophic chondrocytes of E16.5 CAG-Sox9;Col10a1-Cre embryos was performed using an anti-HA antibody. f Expression of chondrocyte markers in CAG-Sox9;Col10a1-Cre embryos. Histological analysis of forelimbs of CAG-Sox9;Col10a1-Cre embryos stained with Safranin O and von Kossa staining at E17.5. Sections of the forelimbs of E17.5 CAG-Sox9 and CAG-Sox9;Col10a1-Cre embryos were hybridized with Col2a1, Col10a, and Mmp13 probes clone [15] . Recent studies showed that Sox9 inhibits Runx2 functions through direct binding to Runx2 [16] . Furthermore, Sox9 negatively regulates Runx2 by enhancing Bapx1 expression, which leads to the inhibition of terminal chondrocyte differentiation [17] . Therefore, these studies support the existence of a mechanism in which misexpression of Sox9 in hypertrophic chondrocytes of CAGSox9;Col2a1-Cre and CAG-Sox9;Col10a1-Cre mice results in inhibition of terminal differentiation through suppression of Runx2.
Conclusion
Transgenic mice for Sox9 conditional overexpression that we have generated will constitute a very valuable tool to further uncover the multiple tissue-specific functions of Sox9 in vivo. It will facilitate studies on the roles of Sox9 in developmental, physiological, and pathological processes from embryogenesis into adulthood.
